| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OXT |
| Uniprot No | P01178 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-125aa |
| 氨基酸序列 | AAPDLDVRKCLPCGPGGKGRCFGPNICCAEELGCFVGTAEALRCQEENYLPSPCQSGQKACGSGGRCAVLGLCCSPDGCHADPACDAEATFSQR |
| 预测分子量 | 11.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于OXT(催产素)重组蛋白研究的模拟参考文献(注：文献为虚构示例，实际文献请通过学术数据库检索)：
1. **《重组OXT蛋白在大鼠社交行为中的调节作用》**
- 作者：Smith A, et al.
- 摘要：通过基因重组技术表达OXT蛋白，研究其在啮齿类动物模型中改善社交障碍的效果，证明重组OXT可通过血脑屏障调节神经信号通路。
2. **《高效表达系统优化人源OXT重组蛋白的制备》**
- 作者：Zhang L, et al.
- 摘要：利用大肠杆菌表达系统优化重组OXT蛋白的分泌表达条件，获得高纯度产物，为规模化生产提供技术参考。
3. **《重组OXT融合蛋白的鼻内给药与焦虑治疗》**
- 作者：Johnson R, et al.
- 摘要：开发一种OXT与穿透肽融合的重组蛋白，通过鼻内给药显著提高生物利用度，并在焦虑模型小鼠中观察到快速抗焦虑效果。
建议通过PubMed、Web of Science等平台，以关键词“recombinant oxytocin protein”、“OXT expression”或“oxytocin therapeutic application”检索真实文献。
OXT (oxytocin) recombinant protein is a synthetically produced version of the neuropeptide oxytocin, a hormone and neurotransmitter with critical roles in human physiology and behavior. Naturally secreted by the posterior pituitary gland, oxytocin regulates childbirth, lactation, and social bonding. Its therapeutic and research applications have driven demand for high-purity, scalable production, leading to the development of recombinant OXT using genetic engineering techniques.
Recombinant OXT is typically generated by inserting the human OXT gene into expression systems like *E. coli* or mammalian cell lines. Host cells are engineered to produce the precursor protein, which undergoes enzymatic cleavage to yield the active nonapeptide (nine-amino-acid sequence). Advanced purification methods, including chromatography, ensure the removal of contaminants, enhancing safety for clinical use. Unlike animal-derived oxytocin, recombinant versions minimize batch variability and ethical concerns associated with extraction from biological sources.
The recombinant form retains oxytocin’s bioactivity, binding to oxytocin receptors in the brain and peripheral tissues. It is widely used in obstetrics to induce labor and control postpartum hemorrhage. Research also explores its potential in treating neuropsychiatric disorders (e.g., autism, social anxiety) due to its role in modulating trust and empathy. However, challenges persist in delivering OXT across the blood-brain barrier, prompting studies on intranasal formulations or nanoparticle-based delivery systems.
Commercial OXT recombinant proteins serve as essential tools in neuroscience, endocrinology, and drug development. Their standardized production supports both mechanistic studies and clinical trials, though long-term effects and dosing protocols require further validation. Overall, recombinant OXT exemplifies the intersection of biotechnology and neuroendocrinology, offering scalable solutions for therapeutic and experimental needs.
×
